SCHEMBL206928

SCHEMBL206928

Fc1ccc2o[c]cc2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.38
CYP2A6 P11509 1/20 0.38
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
AHR P35869 1/20 0.33
BACE1 P56817 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
APP P05067 1/20 0.31
PGR P06401 2/20 0.31
GABRP O00591 1/20 0.30
GABRD O14764 1/20 0.30
GABRA1 P14867 1/20 0.30
GABRB1 P18505 1/20 0.30
GABRG2 P18507 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207069 0.83 CYP1A2 (0.38) CYP1A2CYP2A6AHRBACE1APP
SCHEMBL207520 0.74 CYP2A6 (0.44) CYP1A2CYP2A6CA12CA1CA2
SCHEMBL146387 0.74 CYP2A6 (0.40) CYP2A6CA12CA1CA2CA9
SCHEMBL4146968 0.74 ALDH1A1 (0.41) CYP1A2CA2CHRM2
SCHEMBL207632 0.74 MAOB (0.41) CYP1A2CYP2A6CA12CA1CA2
SCHEMBL3378032 0.74 CA12 (0.42) CYP1A2CA12CA1CA2CA9
SCHEMBL533590 0.74 PIM1 (0.44) BACE1PGR
SCHEMBL207573 0.72 GABRP (0.47) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL533195 0.70 ALOX15 (0.34)
SCHEMBL533282 0.69 CYP2A6 (0.47) CYP1A2CYP2A6CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118164975-A Quaternary ammonium salt oxazolidinone derivative and pharmaceutically acceptable salt thereof, preparation method and application 中国医学科学院医药生物技术研究所 2024-06-11 CN claimed
US-11878981-B2 Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-01-23 US claimed
WO-2022255900-A1 CYSTEINYL LEUKOTRIENE RECEPTOR LIGANDS DIRECTED TOWARD THE TREATMENT OF INFLAMMATORY AND ONCOLOGICAL DISEASES федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (национальный исследовательский университет)" 2022-12-08 WO claimed
CN-109997061-B Optical laminate, circularly polarizing plate, touch panel, and image display device 日本瑞翁株式会社 2022-07-15 CN claimed
EP-3197277-B1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION INC (US) 2021-12-22 EP claimed
US-20170283439-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CCHDI Foundation Inc. (US) 2017-10-05 US claimed
EP-3197277-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI Foundation, Inc. (US) 2017-08-02 EP claimed
WO-2016033440-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN CHDI FOUNDATION, INC. (US) 2016-03-03 WO claimed
EP-1778639-B1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RES INC (US) 2015-09-02 EP claimed
EP-1577301-B1 Antithrombotic diaminocyclohexane derivatives DAIICHI SANKYO CO LTD (JP) 2012-09-12 EP claimed
US-20030144175-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2003-07-31 US claimed
EP-1307203-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-05-07 EP claimed
EP-1307204-A1 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2003-05-07 EP claimed
EP-1270557-A1 ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-01-02 EP claimed
US-20020147188-A1 Protease inhibitors SMITHKLINE BEECHAM CORPORATION 2002-10-10 US claimed
EP-1158986-A4 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORP (US) 2002-03-27 EP claimed
WO-2001095911-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-12-20 WO claimed
EP-1158986-A1 PROTEASE INHIBITORS SmithKline Beecham Corporation (US) 2001-12-05 EP claimed
WO-2001070232-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2001-09-27 WO claimed
WO-2000038687-A1 PROTEASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2000-07-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170283439-A1 PROBES FOR IMAGING HUNTINGTIN PROTEIN HTT, HYPK, HSPBP1 CYP1A2 4836/4885CYP2A6 4875/4885CA12 2572/4885
US-11878981-B2 Substituted 1,2,4-oxadiazoles as TRPA1 inhibitors TRPA1, TRPV1, TRPV3 CYP1A2 2352/4885CYP2A6 3019/4885CA12 4823/4885
US-20020147188-A1 Protease inhibitors CTSK, MMP13, CTSZ CYP1A2 2704/4885CYP2A6 1414/4885CA12 570/4885
US-20030144175-A1 Protease inhibitors CTSK, MMP13, CTSZ CYP1A2 2704/4885CYP2A6 1414/4885CA12 570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.